cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
September 26.2026
3 Minutes Read

How Switzerland's SCRIPT Trial Is Shaping Cannabis Consumption Trends

Switzerland’s SCRIPT Trial Finds Regulated Cannabis Sales Change How People Consume, Not How Much

Unlocking New Insights in Cannabis Consumption

In recent years, European nations such as Switzerland have taken bold steps towards understanding the impacts of regulated cannabis sales. Notably, the SCRIPT pilot program has emerged, providing evidence that access to legal cannabis doesn’t necessarily lead to increased consumption, but instead can alter the way people consume. As cannabis markets evolve, stakeholders must pay attention to these pioneering studies.

Understanding SCRIPT: A Step Towards Safer Cannabis

The SCRIPT (Safer Cannabis: Research In Pharmacies randomised controlled Trial) program, initiated by researchers from the University of Bern and the University of Lucerne, is a significant endeavor aimed at analyzing the effects of regulated cannabis distribution through pharmacies. Launched in May 2024, the study is set to run until 2029, exploring how access to legal products influences both health outcomes and social behaviors regarding cannabis use.

The Data Speaks: Initial Findings from SCRIPT

The first interim findings reveal fascinating trends. Among the users who had legal access to cannabis, a notable 75% reported consuming cannabis within a week of the study. Interestingly, over half of these participants (51%) sourced their cannabis from the study pharmacies, while a significant portion still relied on illegal markets. However, it appears that regulatory measures are subtly shifting consumer preferences, with a preference for lower-risk consumption methods like vaping rather than smoking.

Illuminating Impact on the Illicit Market

One primary aim of SCRIPT is to understand how legal access affects the illicit market. As seen, individuals in the access group are still utilizing illegal sources for cannabis, albeit at a reduced rate compared to those who only relied on illicit options. This suggests that regulated supply does not completely eliminate the black market, but it changes user habits, making it vital for policymakers to consider how to enhance legal access strategically.

Regulatory Considerations: Taxation and Pricing

Another aspect closely examined in SCRIPT is the implementation of simulated tax rates on cannabis products. The current tax rates are among the highest seen in pilot initiatives at CHF3 to CHF4 per gram for flower. This deliberate pricing structure allows researchers to gauge consumer reactions under realistic market conditions, providing invaluable data for future regulations.

Broader Implications for Public Health and Safety

Could the findings from SCRIPT redefine our understanding of cannabis safety? Preliminary data suggests not only shifts in consumption patterns but also a potential reduction in associated harms. It’s noteworthy that, despite the varied sources of cannabis, participants reported minimal severe adverse events. The approach integrates a paid counseling service for participants, which promotes responsible consumption and offers insights into harm-reduction practices.

A Bridge Between Science and Society

As SCRIPT continues to unfold, it sets an important precedent for how regulatory frameworks can adapt based on scientific findings. Researchers are paving the way for future policies that align with real-world data, ensuring that cannabis markets prioritizing public health and consumer safety can flourish. The dialogue sparked by SCRIPT serves not only as an academic curiosity but as a foundation for countries poised to explore their own paths towards cannabis legislation.

With the burgeoning cannabis industry on the horizon, now is the time for executive cannabis professionals to engage with these studies, considering how they can harness insights from SCRIPT to shape their strategies moving forward.

Brands

3 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

What the Netherlands’ Landmark Cannabis Experiment Reveals for Professionals

Update A Deep Dive Into the Netherlands’ Cannabis Experiment Results The Netherlands has long been a leader in cannabis policy reform, and its recent landmark experiment to establish a controlled cannabis supply chain is bringing significant attention. Initial findings from this ambitious initiative were presented to the House of Representatives on September 9, marking the first published results since the T0 baseline report in March 2024. These new data provide valuable insights as they cover the period from April 7, 2025, onwards, reflecting the first full year of fully regulated cannabis sales. Understanding the Initial Findings While numerous production delays affected the rollout, all ten municipalities have officially entered the experiment, allowing them to transition from a mix of regulated and illicit cannabis to full compliance with regulated supply. As of April 7, 2025, all cannabis sold in registered coffeeshops must come from licensed growers. The research consortium—comprised of Breuer&Intraval, RAND Europe, and the Trimbos-instituut—compared consumer behavior in the intervention municipalities against areas where the illicit market continues to thrive. Interestingly, the data revealed that while visitor numbers and self-reported cannabis usage remained stable across all coffeeshops, concerns about neighborhood livability have slightly increased. Reports of loitering, noise, and traffic rose among residents, which serves as a critical benchmark for assessing the impact of cannabis legalization on local communities. Impact on the Illicit Market Despite the establishment of regulated markets, many consumers reported purchasing illicit cannabis, citing lower prices and perceived value as significant factors. This challenges the very intent of the experiment—to curb the illicit market by providing safer and regulated alternatives. Notably, illegal hash purchases actually increased in intervention areas, presenting an intriguing dynamic for lawmakers who may have anticipated a decrease in such activities. Challenges for Consumers and Producers While all stakeholders recognize the benefits of regulation, concerns have arisen around high-THC products, such as edibles and concentrates. The Ministry of Justice has acknowledged these worries, prompting them to revise product leaflets and commit to regular consultations with municipalities to enhance consumer education regarding dosing and risks. A Glimpse at Future Predictions and Opportunities As the experiment proceeds, further follow-up reports (T2 and T3) are anticipated before a comprehensive evaluation in 2028. The Netherlands’ decision on the program’s future in 2029 could set important precedents for other countries contemplating similar initiatives. For cannabis professionals, understanding the evolving dynamics within this experiment holds immense potential for strategic planning and market positioning. Amid the challenges and successes, the evolving market landscape in this pioneering program will likely attract global interest, especially in how supply and demand shift in real-time. As the industry develops, insights gained here can serve as a template for others looking to navigate the complex world of cannabis regulation. For those vested in this growing industry, the findings from the Netherlands underscore the importance of staying informed and adaptable. With trends swinging from supply shortages to concerns about overproduction, it emphasizes that cannabis regulation still presents opportunities for proactive strategies within the market.

Cannabis Europa's 2027 Events: A Flagship Move and Growing European Presence

Update Exciting Changes Ahead for Cannabis Europa 2027 As a beacon of innovation in the cannabis sector, Cannabis Europa is making waves with its newly announced events for 2027. Following record demand and feedback from previous attendees, this leading cannabis conference series will take its flagship event to a new venue, Woolwich Works. Scheduled for June 23-24, 2027, this gathering will mark the first venue shift since its time at the Barbican, reflecting the continuous growth of the industry. More Room for Growth in a Flourishing Market With over 2,000 delegates and more than 70 exhibitors expected, the move to Woolwich provides additional floor space to accommodate the growing interest in cannabis across Europe. The UK’s medical cannabis market, which skyrocketed in growth by 103% in 2025, is a testament to the increasing acceptance and expansion within the sector. It’s vital for industry professionals to understand the dynamics driving this momentum, particularly as nearly 390,000 medical cannabis patients are projected by 2032. However, it’s worth noting that access remains challenging through NHS pathways, with many patients resorting to private clinics for treatment. Expanding Horizons: New European Cities to Join the Calendar In addition to the flagship event in London, Cannabis Europa is set to launch two further gatherings in Europe, details of which will be revealed over the coming weeks. Each event will offer a more intimate setting, gathering 200-300 delegates. These locales are chosen carefully to highlight the burgeoning cannabis markets in their respective regions. Industry stakeholders must keep an eye on these developments to capitalize on local opportunities that could shape the future of cannabis legislation and market trends. A Vision for Community-Building in Cannabis Stephen Murphy, Founder & CEO of Prohibition Partners Group, expresses a heartfelt sentiment about the shift from the Barbican to Woolwich. He emphasizes Woolwich's rich history in trade and commerce, asserting that it symbolizes the growth and ambition of the cannabis sector. This transition is more than just a logistical move; it represents a commitment to fostering conversations and collaborations that can shape the future of cannabis in Europe. Joining the Conversation at Cannabis Europa For industry professionals ready to engage in this pivotal moment for cannabis in Europe, tickets for Cannabis Europa London are available now. Additionally, sponsorship and speaker applications are open, presenting an opportunity for key players to showcase their insights and services across all three events. Elevating your company's presence at these gatherings can significantly enhance your visibility in this dynamic landscape. Be a Part of the Change The Cannabis Europa gatherings are driven by the passion of individuals dedicated to advancing the cannabis conversation. With the industry rapidly evolving, it’s more important than ever for professionals to connect, share ideas, and collaborate. These events are not just conferences; they are a celebration of the community building happening within the space. Don't miss your chance to be a part of this exciting journey!

CBD Regulation in the UK: The Inevitable Shift Towards EU Authorisations

Update Brussels: The Potential Overlord of the UK CBD Sector The future of Britain's burgeoning CBD industry might not hinge solely on domestic regulation, but rather on the looming shadow of EU authorisations. Professor Susan Jebb, chair of the Food Standards Agency (FSA), recently stated in a board meeting that the long-term fate of the country’s CBD sector is likely to be dictated by Brussels. After years of navigating the often complex and protracted novel foods approval process in the UK, this revelation is more than just a bureaucratic detail; it reflects a potential paradigm shift in how CBD products may be regulated in Britain. A Milestone Marked by Irony During the same meeting where the FSA recommended the first three high-purity CBD applications for government authorisation, Jebb's admission echoed a bittersweet irony for producers who have invested time and resources into the process. Despite seemingly making progress, they face the potential nightmare of additional hurdles if alignment with EU regulations demands even stricter limits. The current acceptable daily intake (ADI) for CBD has already been set at a relatively low 10mg; the EU’s stringent standards may push that figure down further, posing dire challenges for manufacturers. What Lies Ahead for CBD Regulation? As the European Food Safety Authority (EFSA) recently determined an acceptable intake level for CBD at just 2mg per day, the UK must evaluate its position on the global regulatory landscape. Businesses operating in the CBD sector will need to prepare for a reality that could see them having to apply for EU authorisations to remain viable within the UK market. Jebb emphasizes the importance of the ongoing risk-management decisions that the FSA makes, suggesting that these could influence future international standards, showcasing the interconnected nature of food safety across borders. Implications for CBD Industry Stakeholders The implications of these dynamic alignments are significant. Stakeholders must brace for a landscape where all current UK authorisations could be rendered moot, requiring a pivot towards compliance with EU regulations instead. Manufacturers who initially thought they were navigating a clear path may find themselves needing to reformulate their products on the fly, potentially abandoning efforts altogether if compliance proves too costly or complicated. It begs the question: can UK businesses adapt quickly enough to survive and thrive in this evolving framework? Why This Matters to the Industry Understanding these regulatory transitions is crucial for cannabis professionals. As the industry faces tightening scrutiny and evolving regulations, the need for strategic foresight cannot be overstated. The FSA’s candid acknowledgment that the future lies with EU authorisations reinforces the urgency for UK stakeholders to engage with these regulatory changes early and thoroughly. Your Next Steps in the CBD Landscape For those actively participating in the CBD sector, the key takeaway is clear: stay informed and adaptable. Regularly review updates from both the FSA and EFSA, and assess how these regulations directly impact your operational strategy. For cannabis professionals, aligning product development with an understanding of both UK and EU standards will be vital for continued success in this dynamic industry.

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*